Suchergebnisse - "Berlaimont, Valérie"

PubPharm (20)

1

Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g : A systematic literature review

enthalten in: Human vaccines & immunotherapeutics | 2023

von Knuf, M. | Charkaluk, M. | The Nguyen, P. | +5

2

Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants : Mathematical projections in six countries

enthalten in: Human vaccines & immunotherapeutics | 2023

von George, M. | Pérez Martin, J. | AbdelGhany, M. | +6

3

Vaccination in preterm and low birth weight infants in India

enthalten in: Human vaccines & immunotherapeutics | 2022

von Soans, S. | Mihalyi, A. | Berlaimont, V. | +3

4

Diphtheria-tetanus-pertussis (DTP) vaccination : understanding the perspectives and expectations of parents and healthcare professionals in France and India

enthalten in: Human vaccines & immunotherapeutics | 2022

von Bakhache, P. | Yewale, V. | Parikh, R. | +4

5

Hexavalent vaccines : What can we learn from head-to-head studies?

enthalten in: Vaccine | 2021

von Knuf, M. | Haas, H. | Garcia-Corbeira, P. | +4

6

Predicted long-term antibody persistence for a tick-borne encephalitis vaccine : results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules

enthalten in: Human vaccines & immunotherapeutics | 2020

von Costantini, M. | Callegaro, A. | Beran, J. | +2

CommentIn: Hum Vaccin Immunother. 2020 Sep 1;16(9):2280-2281. - PMID 32701398

7

Response letter : "Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules"

enthalten in: Human vaccines & immunotherapeutics | 2020

von Costantini, M. | Callegaro, A. | Beran, J. | +2

CommentOn: Hum Vaccin Immunother. 2020 Sep 1;16(9):2274-2279. - PMID 31951780

8

Response to 'Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England : data to end 2017' by Checchi et al

enthalten in: Sexually transmitted infections | 2019

von Berlaimont, V. | Welby, S.

CommentOn: Sex Transm Infect. 2019 Aug;95(5):368-373. - PMID 30723186

9

Post-hoc analysis from phase III trials of human papillomavirus vaccines : considerations on impact on non-vaccine types

enthalten in: Expert review of vaccines | 2019

von Ryser, M. | Berlaimont, V. | Karkada, N. | +3

10

Letter-to-the-Editor in response to "Tanton C, et al. Human papillomavirus (HPV) in young women in Britain : Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001."

enthalten in: Papillomavirus research (Amsterdam, Netherlands) | 2018

von Ryser, M. | Guignard, A. | Berlaimont, V.

CommentOn: Papillomavirus Res. 2017 Jun;3:36-41. - PMID 28626810